Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.05 -0.16 (-0.99%)
Streaming Delayed Price Updated: 1:41 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139,137
Open 16.34
Bid (Size) 16.05 (500)
Ask (Size) 16.09 (300)
Prev. Close 16.21
Today's Range 16.05 - 16.34
52wk Range 13.09 - 18.91
Shares Outstanding 353,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma t... 
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
From Bausch + Lomb
Via Business Wire

Performance

YTD
-3.2%
-3.2%
1 Month
+7.0%
+7.0%
3 Month
-3.4%
-3.4%
6 Month
-8.3%
-8.3%
1 Year
+17.3%
+17.3%

More News

Read More
News headline image
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Via StockStory
News headline image
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Small-Cap Stocks We Steer Clear Of
Via StockStory
News headline image
1 Stock Under $50 to Own for Decades and 2 We Turn Down
Via StockStory
News headline image
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest
Via StockStory
News headline image
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Profitable Stocks We’re Skeptical Of
Via StockStory
News headline image
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
Via StockStory
News headline image
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For
Via StockStory
News headline image
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Releases 2025 Sustainability Impact Report
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch Lomb BLCO Q2 2025 Earnings Transcript ↗
Via The Motley Fool

Frequently Asked Questions

Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 16.05
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 07/14/26 01:41 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 5.68B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.